Proactive Investors - Run By Investors For Investors

WideCells Group formally inks revenue generating overseas deal

First announced on October 11, the binding agreement with White Apex General Trading formally came into effect on Tuesday
Doctor with shot
The agreement takes the company's unique stem cell offering to the Middle East, North Africa and Asia

The stem cell specialist WideCells Group plc said it has concluded a revenue-generating deal that will see its unique services sold in the Middle East, North Africa and Asia.

First announced on October 11, the binding agreement with White Apex General Trading formally came into effect on Tuesday (Oct 31).

READ: WideCells ready to ink deal that expands its reach to the Middle East, Africa and Asia-Pacific

It triggers the immediate payment of £255,000 to the London-listed company to cover the initial set up of stem cell collection and dispatch services, and Wideacademy, which provides education and training for doctors.

Recurring revenues expected

A further £1.5mln is potentially payable for the adaptation of Wideacademy's platform for use in the Middle East, North Africa and Asia-Pacific regions.

The firm also expects “multi-million pound” recurring revenue from three key sources: CellPlan, its stem cell insurance product; storage and its synthetic bone product and the Wideacademy.

“Stem cells are revolutionising the medical world, and as we build our global reach we are also able to promote and support the development of this rapidly growing area of medicine so that more and more people can benefit from and have access to this potentially life-saving treatment,” said Widecells chief executive João Andrade.

"White Apex make the perfect partner for us.  Thanks to their unrivalled regional experience and connections within the MENA and Asia-Pacific territories, we are able to rapidly build our global presence and commercial reach.”

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use